围术期免疫昼夜节律恢复表型与结直肠癌术后ctDNA-MRD及长期生存的关联
该前瞻性观察队列纳入1000例II-III期结直肠癌根治性切除患者,基于可穿戴设备睡眠/活动/心率与炎症免疫标志物整合出三种围术期免疫昼夜节律恢复表型。延迟恢复表型与术后ctDNA-MRD阳性率升高及无病生存和总生存下降相关,且在调整ctDNA-MRD后关联仍存在。
要点
- 围术期免疫昼夜节律恢复可分为快速、中间和延迟三种表型。
- 延迟恢复表型与术后ctDNA-MRD阳性风险升高独立相关。
- 恢复表型可补充临床病理因素和ctDNA-MRD的预后信息。
核心结论
- 围术期免疫昼夜节律恢复表型与结直肠癌术后ctDNA-MRD阳性及长期肿瘤学结局相关。
- 恢复表型提供了独立于临床病理因素和ctDNA-MRD的补充信息。
- 该研究性表型需独立外部验证后方可用于指导术后临床管理。
研究设计与样本
- 通过整合可穿戴设备睡眠、静息-活动节律和心率指标与术前至术后第30天的系列炎症和免疫标志物,推导围术期免疫昼夜节律恢复表型。
- 采用多变量logistic回归评估与术后ctDNA-MRD阳性的关联,采用多变量Cox回归和术后第30天landmark分析评估与无病生存和总生存的关联。
主要发现
- 共识别三种恢复表型:快速恢复382/1000(38.2%)、中间恢复401/1000(40.1%)、延迟免疫昼夜节律恢复217/1000(21.7%)。
- 术后ctDNA-MRD阳性率从快速恢复组的8.9%(34/382)升高至中间恢复组的17.0%(68/401)和延迟恢复组的30.0%(65/217)。
- 与快速恢复相比,延迟恢复与术后ctDNA-MRD阳性风险升高相关(调整OR 3.94;95%CI 2.45-6.33)。
- 60个月时,三组估计无病生存率分别为82.1%、76.4%和63.8%,估计总生存率分别为90.0%、86.9%和77.2%。
- 在未调整ctDNA-MRD的模型中,延迟恢复与较差无病生存(调整HR 2.21;95%CI 1.64-2.98)和总生存(调整HR 2.03;95%CI 1.45-2.85)相关;额外调整ctDNA-MRD后相应调整HR分别为1.90(95%CI 1.40-2.57)和1.80(95%CI 1.28-2.53)。
临床怎么用
- 围术期免疫昼夜节律恢复表型有望辅助识别ctDNA-MRD阳性及长期预后不良的高危患者。
- 该表型目前仍属研究性质,需外部验证后方可用于指导术后临床管理。
局限性
- 研究性表型需独立外部验证后方可用于指导术后临床管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative outcomes after curative colorectal cancer surgery vary widely, even among patients with comparable tumor characteristics and treatment pathways. Conventional clinicopathologic factors and circulating tumor DNA predominantly characterize tumor-related risk but provide limited information regarding the dynamic host response to surgical stress. We investigated whether distinct perioperative immunocircadian recovery trajectories could be identified and whether these trajectories were associated with postoperative circulating tumor DNA-based minimal residual disease and long-term oncologic outcomes. METHODS: This prospective observational cohort study included 1,000 patients with stage II-III colorectal cancer who underwent curative-intent resection between June 2017 and December 2019 and were scheduled for oncologic follow-up through 60 months. Perioperative immunocircadian recovery phenotypes were derived by integrating longitudinal wearable-based sleep, rest-activity rhythm, and heart-rate measures with serial inflammatory and immune markers collected from the preoperative period through postoperative day 30. Associations with postoperative circulating tumor DNA-minimal residual disease positivity were assessed using multivariable logistic regression, whereas associations with disease-free survival and overall survival were assessed using multivariable Cox regression and a postoperative day 30 landmark analysis. RESULTS: Three distinct recovery phenotypes were identified: rapid recovery (382/1,000; 38.2%), intermediate recovery (401/1,000; 40.1%), and delayed immunocircadian recovery (217/1,000; 21.7%). Postoperative circulating tumor DNA-minimal residual disease positivity increased from 8.9% (34/382) in the rapid-recovery group to 17.0% (68/401) in the intermediate-recovery group and 30.0% (65/217) in the delayed-recovery group. Compared with rapid recovery, delayed recovery was associated with greater odds of postoperative circulating tumor DNA-minimal residual disease positivity (adjusted odds ratio, 3.94; 95% confidence interval, 2.45-6.33). At 60 months, estimated disease-free survival was 82.1%, 76.4%, and 63.8%, respectively, and estimated overall survival was 90.0%, 86.9%, and 77.2%, respectively. In models adjusted for clinicopathologic factors but not circulating tumor DNA-minimal residual disease, delayed recovery was associated with worse disease-free survival (adjusted hazard ratio, 2.21; 95% confidence interval, 1.64-2.98) and overall survival (adjusted hazard ratio, 2.03; 95% confidence interval, 1.45-2.85). After additional adjustment for postoperative circulating tumor DNA-minimal residual disease, the corresponding adjusted HRs were 1.90 (95% confidence interval, 1.40-2.57) and 1.80 (95% confidence interval, 1.28-2.53), respectively. Addition of the recovery phenotype to a clinicopathologic model that included circulating tumor DNA-minimal residual disease increased the optimism-corrected C-index for disease-free survival from 0.754 to 0.781. CONCLUSION: Distinct perioperative immunocircadian recovery phenotypes were associated with postoperative circulating tumor DNA-minimal residual disease positivity and long-term oncologic outcomes after colorectal cancer surgery. The recovery phenotype provided information complementary to clinicopathologic factors and circulating tumor DNA-minimal residual disease within the study cohort. However, this investigational phenotype requires independent external validation before it can be used to guide postoperative clinical management.
引用
- Pan S, Wang G. Perioperative immunocircadian recovery and its association with circulating tumor DNA-based minimal residual disease and long-term survival after colorectal cancer surgery. Surgery. 2026. PMID: 42697086. doi:10.1016/j.surg.2026.110539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。